GSK plc at JPMorgan Healthcare Conference Transcript

Jan 09, 2024 / 03:30PM GMT
James Daniel Gordon - JPMorgan Chase & Co, Research Division - Senior Analyst

Good morning. I'm James Gordon, JPMorgan European pharma and biotech analyst. And today, I've got the pleasure of introducing the GSK presentation. You're going to hear from GSK CEO, Emma Walmsley.

Thanks a lot for joining us today, Emma. I look forward to the presentation.

Emma Natasha Walmsley - GSK plc - CEO & Director

Thank you so much, James, and good morning. A very happy new year to you all. It is absolutely wonderful to attend today's conference and to share with everybody the progress that GSK is making. Please turn to Slide 2.

This is, of course, the usual cautionary statement, and we'll comment on our performance and forward-looking statements using constant exchange rates, or CER, unless stated otherwise. Please turn to Slide 3. GSK is a global biopharma company focused on the prevention and the treatment of disease with clear performance momentum as we head into 2024.

In the first 9 months of 2023, we delivered double-digit sales and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot